Cargando…
(131)I–Tositumomab in lymphoma
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of (131)I–tositumomab in non-Hodgkin lymphoma (nhl) have suggested benefit in patients with relapsed or refractory indolent disease. However, the ro...
Autores principales: | Cheung, M.C., MacEachern, J.A., Haynes, A.E., Meyer, R.M., Imrie, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768513/ https://www.ncbi.nlm.nih.gov/pubmed/19862360 |
Ejemplares similares
-
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007) -
Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
por: Burdick, Michael J, et al.
Publicado: (2009) -
Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline
por: Reece, D., et al.
Publicado: (2006) -
Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
por: Buchegger, F, et al.
Publicado: (2006) -
Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)